drugset / Trial / NCT05305768
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Xeomin in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2023-02
- Completion
- 2023-02
Publications
- Background Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004 Nov;114(6 Suppl):1S-22S. doi: 10.1097/01.PRS.0000144795.76040.D3.
- Background Prager W, Bee EK, Havermann I, Zschocke I. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging. 2013;8:449-56. doi: 10.2147/CIA.S34854. Epub 2013 Apr 24.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
Indications
No indication recorded.